Filing Flows › Comparisons › PRME vs IMA
Prime Medicine vs ImageneBio: PRME and IMA compared
Prime Medicine is the larger company: $838K of revenue in its latest quarter (Q4 2025) against $800K for ImageneBio (Q1 2025).
Where the money goes: PRME and IMA
Prime Medicine (PRME) · Q4 2025
Prime Medicine, Q4 2025: revenue $838K (-62% year over year), net loss $46.1M, operating cash flow −$37.3M. The chart follows the revenue to costs, profit and cash.
ImageneBio (IMA) · Q1 2025
ImageneBio, Q1 2025: revenue $800K, net loss $8.6M, operating cash flow −$10.6M. The chart follows the revenue to costs, profit and cash.
| Prime Medicine (PRME) | ImageneBio (IMA) | |
|---|---|---|
| Latest quarter | Q4 2025 | Q1 2025 |
| Revenue | $838K | $800K |
| Revenue growth, Y/Y | -62% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$46.1M | −$8.6M |
| Operating cash flow | −$37.3M | −$10.6M |
Questions
Which is bigger, Prime Medicine or ImageneBio?
Prime Medicine is the larger company: $838K of revenue in its latest quarter (Q4 2025) against $800K for ImageneBio (Q1 2025).
More: Prime Medicine earnings · how Prime Medicine makes money · ImageneBio earnings · how ImageneBio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 3, 2026; 10-Q filed May 8, 2025). Fiscal quarters can end on different dates. Not investment advice.